Home page News Related Researches 2020-2029

The effect of melatonin on sleep quality and insomnia in patients with cancer: a systematic review study

Published on Friday, 01 April 2022

Abstract

Background: Considering the importance of sleep in the treatment success and quality of life in patients with cancer, it is necessary to seek effective solutions to improve their sleep quality. In this regard, a comprehensive review of the effect of melatonin on sleep can be very useful to provide an evidence-based clinical guide. Therefore, the aim of the present systematic review was to investigate effect of melatonin on sleep quality and insomnia in patients with cancer.

Methods: The present systematic review was conducted in 2021. To find evidence related to the study objective, Iranian databases (SID, Magiran) and international databases (Google scholar, Web of Science, ProQuest, Medline via PubMed, Scopus) were searched using specified keywords (Melatonin, Sleep, insomnia, Cancer, Neoplasms, Carcinomas, Tumor, Carcinomatosis, Carcinomatoses, Sarcomas) from the beginning of the establishment of the mentioned databases until 31st December of 2020. After primary and secondary screening, and selection of studies according to inclusion and exclusion criteria, information obtained from studies were extracted in a checklist with items such as author (year), study design, sample size, age, melatonin dose, duration of intervention, results, and conclusion.

Results: From 295 articles found, finally six relevant studies entered the review process. The intervention used in the studies included oral melatonin administration. The minimum and maximum dose of melatonin was 3 mg and 20 mg, respectively, which was taken by patients for 10 days and to four months, usually every night before bedtime in studies. The results of the review showed that melatonin had a significant effect on sleep quality and insomnia in four studies. However, two studies showed no significant improvement on sleep quality after the intervention and melatonin administration, although melatonin had significant effect on increasing sleep efficiency in the short term.

Conclusions: The present review study showed that melatonin may be effective in improving sleep quality and insomnia in patients with cancer. It is suggested to carry out further extensive and detailed studies to achieve the most effective and safest method of melatonin administration in terms of dose and duration of use in order to improve sleep quality among patients with cancer.

Download the complete article

About this publication.

- The Di Bella Method (A Fixed Part - Melatonin tablets. From 30-40mg/day up to 200mg/day orally in patients with advanced stage of cancer disease and/or patients without respond to traditional treatments);

- Melatonin use in cancer patients have started in 1974, when melatonin prepared according to Prof. Di Bella’s formulation [...]. For 11 days was administered to the patient, admitted to the general medical ward at the Maggiore-Pizzardi Hospital in Bologna, very slowly (over approx. 8 hours) and intravenously administered 1000 mg of melatonin for 11 days. During the course of each day, the patient was intravenously administered 4 saline drips of 500 ml, each containing ten 25 mg bottles of freeze-dried melatonin, lasting 2 hours, totaling 1000 mg per day. No other drug of any kind was administered in order to ascertain the effect of the MLT without interference [...]. From Melatonin with adenosine solubilized in water and stabilized with glycine for oncological treatment - technical preparation, effectivity and clinical findings;

- About Melatonin - In vitro, review and in vivo publications;

- Publication: Melatonin anticancer effects: Review (from Di Bella's Foundation);

- Publication: Key aspects of melatonin physiology: 30 years of research (from Di Bella's Foundation);

- The Di Bella Method (A Fixed Part - Cyclophosphamide 50mg tablets and/or Hydroxyurea 500mg tablets, one or two per day);

- The Synergism of Somatostatin, Melatonin, Vitamins Prolactin and Estrogen Inhibitors Increased Survival, Objective Response and Performance Status In 297 Cases of Breast Cancer;

- Complete objective response, stable for 5 years, with the Di Bella Method, of multiple-metastatic carcinoma of the breast;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- The Di Bella Method DBM improved survival objective response and performance status in a retrospective observational clinical study on 23 tumours of the head and neck;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;